The present disclosure relates to methods and compositions useful for initiating and propagating ICOS-mediated signaling. In particular, the present disclosure provides three peptide motifs which promote ICOS binding and whose ablation leads to modulated ICOS signaling and modulated signaling mediated by TBK1, IRF4, IKKβ, or TBKBP1. The binding of these peptide motifs or the addition of such motifs as co-stimulatory agents leads to modulated immune responses, and provides new and unexpected therapies for neurodegenerative, autoimmune, metabolic, cancer inflammatory, or immunodeficiency conditions, diseases, or disorders.

The present disclosure relates to methods and compositions useful for initiating and propagating ICOS-mediated signaling. In particular, the present disclosure provides three peptide motifs which promote ICOS binding and whose ablation leads to modulated ICOS signaling and modulated signaling mediated by TBK1, IRF4, IKKβ, or TBKBP1. The binding of these peptide motifs or the addition of such motifs as co-stimulatory agents leads to modulated immune responses, and provides new and unexpected therapies for neurodegenerative, autoimmune, metabolic, cancer inflammatory, or immunodeficiency conditions, diseases, or disorders.

The present invention relates to the technical field of foods and additives that are derived from edible plants. Particularly, the present invention relates to a method for obtaining a product rich in antioxidants, dietary fiber and other nutrients from byproducts of edible plants such as dehydrated pulps and juices derived from fruits and vegetables, obtaining thus a first liquid product (first liquid phase), a second liquid product (second liquid phase), and a first and second solid phases, all of them with multiple beneficial health properties. One of the main effects observed when an individual consumes these products, is a normalization in the levels of triglycerides, total cholesterol, and HDL, and the body weight of this individual is maintained even when under a regime of fat diet.

The present invention relates to the technical field of foods and additives that are derived from edible plants. Particularly, the present invention relates to a method for obtaining a product rich in antioxidants, dietary fiber and other nutrients from byproducts of edible plants such as dehydrated pulps and juices derived from fruits and vegetables, obtaining thus a first liquid product (first liquid phase), a second liquid product (second liquid phase), and a first and second solid phases, all of them with multiple beneficial health properties. One of the main effects observed when an individual consumes these products, is a normalization in the levels of triglycerides, total cholesterol, and HDL, and the body weight of this individual is maintained even when under a regime of fat diet.

A method for producing a carbon dioxide-containing hydrogel article including (1) to (3). (1) Preparing an article including a hydrogel that contains a water-soluble polymer, a cross-linking agent for the water-soluble polymer, and water, wherein a loss tangent of the hydrogel at 1 Hz in dynamic viscoelasticity measurement is 0.46 or greater. (2) Adjusting a composition of an ambient atmosphere of the article including the hydrogel such that a carbon dioxide gas concentration in the ambient atmosphere becomes 10 vol% or greater, and sealing the article including the hydrogel inside a package. (3) Making cross-linking of the hydrogel proceed until the loss tangent, at 1 Hz in dynamic viscoelasticity measurement, of the hydrogel in the article including the hydrogel becomes less than 0.46, and thereby obtaining a carbon dioxide-containing hydrogel article sealed inside the package.

Provided herein are thiazolidinedione analogues that are useful for treating metabolic disorders and/or coronavirus infections. In some embodiments, the metabolic disorder includes insulin resistance, diabetes, or prediabetes. In some embodiments, the coronavirus is COVID-19.

The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

The present disclosure pertains to a composition for treatment of glutaric aciduria and an administration method therefor and, specifically, to a pharmaceutical composition comprising recombinant human glutaryl-CoA dehydrogenase (rhGCDH) for treatment of glutaric aciduria and a method for treating glutaric aciduria, the method comprising a step of administering the pharmaceutical composition. Provided according to an aspect of the present disclosure are a pharmaceutical composition comprising recombinant human glutaryl-CoA dehydrogenase (rhGCDH) for treating glutaric aciduria and a novel method for treating glutaric aciduria through in vivo administration of the pharmaceutical composition (intravenously and subcutaneously; i.v. and s. c.), whereby an excellent effect is brought about through in vivo administration remarkably easier than intraventricular administration, with the expectation of more effectively regulating and treating glutaric aciduria.

The present disclosure pertains to a composition for treatment of glutaric aciduria and an administration method therefor and, specifically, to a pharmaceutical composition comprising recombinant human glutaryl-CoA dehydrogenase (rhGCDH) for treatment of glutaric aciduria and a method for treating glutaric aciduria, the method comprising a step of administering the pharmaceutical composition. Provided according to an aspect of the present disclosure are a pharmaceutical composition comprising recombinant human glutaryl-CoA dehydrogenase (rhGCDH) for treating glutaric aciduria and a novel method for treating glutaric aciduria through in vivo administration of the pharmaceutical composition (intravenously and subcutaneously; i.v. and s. c.), whereby an excellent effect is brought about through in vivo administration remarkably easier than intraventricular administration, with the expectation of more effectively regulating and treating glutaric aciduria.

The present disclosure relates to methods of treating a coenzyme A reduction, elevation, sequestration, toxicity, or redistribution (CASTOR) disease such as, for example, defects in fatty acid oxidation enzymes, methylmalonic acidemia, glutaric acidemia, propionic academia, and HMG-CoA lyase, via small molecule modulators of CoA levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.